We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current INNPF market cap is 55.99M. The company's latest EPS is USD -0.0135 and P/E is -14.81.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 8k | 196k | 2.56M | 13.66M |
| Operating Income | -2.77M | -4.5M | -7.27M | -5.81M | -3.51M |
| Net Income | -3.34M | -9.95M | -10.05M | -3.76M | -3.8M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 2.58M | 4.33M | 12.58M | 6.98M | 6.94M |
| Total Liabilities | 1.17M | 7.94M | 3.56M | 751k | 2.55M |
| Total Equity | 1.41M | -3.61M | 9.01M | 6.23M | 4.39M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -2.72M | -3.69M | -6.63M | -6.07M | -3.9M |
| Investing | -9k | N/A | -48k | -31k | -84k |
| Financing | 4.45M | 4.02M | 15.3M | 125k | 2.92M |
| Market Cap | 55.99M |
| Price to Earnings Ratio | -14.81 |
| Price to Sales Ratio | 4.11 |
| Price to Cash Ratio | 14.49 |
| Price to Book Ratio | 12.8 |
| Dividend Yield | - |
| Shares Outstanding | 280.66M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 1.4k |
| 52 Week Change | 26.55% |
| 52 Week High | 0.3545 |
| 52 Week Low | 0.145 |
| Spread (Intraday) | 0.32 (78.14%) |
| Company Name | InnoCan Pharma Corporation (QB) |
| Address |
1015, 926 - 5 avenue sw calgary, alberta T2P 0N7 |
| Website | https://www.innocanpharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
